Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2025-06-01 DOI:10.1111/1759-7714.70088

Gen Lin, Yongsheng Wang, Tao Xin, Ding Zhang, Qiuyu Zhang, Yangsi Li, Yudan Chi, Yun Fan, Anwen Liu, Haipeng Xu, Liang Shi, Longfeng Zhang, Qian Miao, Xiaobin Zheng, Lijun Li, Kaijia Zhou, Qiwei Yao, Zihua Zou, Kang Miao, Yaping Hong

{"title":"Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.","authors":"Gen Lin, Yongsheng Wang, Tao Xin, Ding Zhang, Qiuyu Zhang, Yangsi Li, Yudan Chi, Yun Fan, Anwen Liu, Haipeng Xu, Liang Shi, Longfeng Zhang, Qian Miao, Xiaobin Zheng, Lijun Li, Kaijia Zhou, Qiwei Yao, Zihua Zou, Kang Miao, Yaping Hong","doi":"10.1111/1759-7714.70088","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer patients with leptomeningeal metastases (LMs) suffer from severe clinical symptoms, poor quality of life, narrow diagnostic and therapeutic time windows, low response to standard treatments, short survival periods, and poor prognoses. At present, there is a lack of precise diagnosis and treatment pathways and relevant consensus for LMs of lung cancer. In order to better guide the clinical diagnosis and treatment of LMs of lung cancer in an early, reasonable, and safe way, the experts of the Neurological Tumor Specialist Committee of the Chinese Society of Clinical Oncology (CSCO) have formulated this consensus based on the actual diagnosis and treatment of LMs of lung cancer in China, with reference to the latest research data, relevant guidelines and consensus, and the experts' clinical experience, as well as the results of experts' polling on the pre-set issues of LMs. The consensus focuses on diagnosing LMs, stratified management, efficacy evaluation systems, treatment strategies, common complications, and palliative care. It gives recommendations in each of the five aspects to provide clinicians with suggestions and references for diagnosing and treating LMs in lung cancer.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70088"},"PeriodicalIF":2.3000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145986/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.70088","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer patients with leptomeningeal metastases (LMs) suffer from severe clinical symptoms, poor quality of life, narrow diagnostic and therapeutic time windows, low response to standard treatments, short survival periods, and poor prognoses. At present, there is a lack of precise diagnosis and treatment pathways and relevant consensus for LMs of lung cancer. In order to better guide the clinical diagnosis and treatment of LMs of lung cancer in an early, reasonable, and safe way, the experts of the Neurological Tumor Specialist Committee of the Chinese Society of Clinical Oncology (CSCO) have formulated this consensus based on the actual diagnosis and treatment of LMs of lung cancer in China, with reference to the latest research data, relevant guidelines and consensus, and the experts' clinical experience, as well as the results of experts' polling on the pre-set issues of LMs. The consensus focuses on diagnosing LMs, stratified management, efficacy evaluation systems, treatment strategies, common complications, and palliative care. It gives recommendations in each of the five aspects to provide clinicians with suggestions and references for diagnosing and treating LMs in lung cancer.

查看原文本刊更多论文

肺癌轻脑膜转移的中国专家共识

肺癌轻脑膜转移（LMs）患者临床症状严重，生活质量差，诊断和治疗时间窗窄，对标准治疗反应低，生存期短，预后差。目前，对于肺癌LMs缺乏精确的诊断和治疗途径及相关共识。为了更好地指导肺癌LMs的早期、合理、安全的临床诊疗，中国临床肿瘤学会神经肿瘤专科委员会专家根据中国肺癌LMs的实际诊疗情况，参考最新的研究数据、相关指南和共识，结合专家的临床经验，制定了本共识。以及专家对lm预设问题的民意调查结果。共识集中于LMs的诊断、分层管理、疗效评估系统、治疗策略、常见并发症和姑息治疗。在五个方面分别提出建议，为临床医生诊断和治疗肺癌LMs提供建议和参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.